Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by GK52N106Won Mar 14, 2011 2:37pm
264 Views
Post# 18282442

RE: Mackie?

RE: Mackie?Schiff, I posed a similar question a few months ago about if the partnership was for ALL of SCT or just a piece of it. I don't recall anyone answering it on this board, but I do believe that it's in fact the hold-up. Partners only want an interest in Stroke - or they want the whole interest in Stroke but nothing to do with M/S or TBI.

How to break things up is the hold-up. I wasn't excited about the whole FDA 20 day or 30 day thing, but I am antsy about something more solid before the end of Q1.
Bullboard Posts